Table 2-1.
Relative survival by tyrosine kinase inhibitor and cumulative response within 1 year
| Group | No. at 5y |
5-y Absolute OS [95% CI] |
5-y Relative OS [95% CI] |
5-y OS in GP |
No. at 10y |
10-y Absolute OS [95% CI] |
10-y Relative OS [95% CI] |
10-y OS in GP |
|---|---|---|---|---|---|---|---|---|
| All TKI Group | ||||||||
| All N=483 | 312 | 92·7 [90·1–95·3] | 94·8 [92·1–97·4] | 97·8 | 127 | 83·5 [79·2–87·9] | 88·3 [83·7–92·9] | 94·6 |
| CCyR N=425 | 284 | 94·5 [92·1–96·9] | 96·6 [94·2–99·1] | 97·8 | 115 | 87·1 [82·7–91·4] | 92·1 [87·4–96·6] | 94·6 |
| MMR N=349 | 234 | 96·5 [94·4–98·7] | 98·7 [96·5–100·9] | 97·8 | 91 | 89·0 [84·5–93·7] | 94·1 [89·3–99·0] | 94·6 |
| MR4·5 N=162 | 105 | 95·8 [92·1–99·4] | 98·1 [94·3–101·7] | 97·7 | 47 | 88·5 [81·9–95·0] | 93·9 [86·9–100·8] | 94·2 |
| CMR N=84 | 53 | 98·6[95·8–100] | 100·9[98·1–102·4] | 97·7 | 21 | 91·7 [82·2–100] | 97·3 [87·3–106·2] | 94·2 |
| Imatinib Group | ||||||||
| All N=271 | 239 | 92·4 [89·2–95·6] | 94·5 [91·2–97·8] | 97·8 | 127 | 83·3 [78·5–88·0] | 88·0 [82·9–92·9] | 94·7 |
| CCyR N=229 | 212 | 94·7 [91·8–97·6] | 96·9 [94·0–99·9] | 97·7 | 115 | 87·4 [82·8––92·0] | 92·8 [87·9–97·7] | 94·2 |
| MMR N=184 | 176 | 97·3 [94·9–99·6] | 99·5 [97·0–101·8] | 97·8 | 91 | 90·0 [85·2––94·8] | 95·1 [90·1–100·2] | 94·6 |
| MR4·5 N=81 | 78 | 97·5 [94·1–100] | 100·1 [96·6–102·7] | 97·4 | 47 | 89·7 [82·9–96·5] | 95·6 [88·4–102·9] | 93·8 |
| CMR N=34 | 33 | 100 | 102·5 | 97·6 | 21 | 93·1 [83·7–100] | 99·0 [89·0–106·4] | 94·0 |
| Dasatinib Group | ||||||||
| All N=107 | 40 | 97·6 [94·1–100] | 99·6 [96·0–102] | 98·0 | 0 | NA | NA | 95·1 |
| CCyR N=99 | 39 | 97·4 [93·7–100] | 99·6 [95·8–102·2] | 97·8 | 0 | NA | NA | 94·7 |
| MMR N=79 | 30 | 98·7 [96·1–100] | 100·9 [98·3–102·2] | 97·8 | 0 | NA | NA | 94·7 |
| MR4·5 N=38 | 12 | 100 | 102·1 | 97·9 | 0 | NA | NA | 94·9 |
| CMR N=27 | 9 | 100 | 102·2 | 97·8 | 0 | NA | NA | 94·7 |
| Nilotinib Group | ||||||||
| All N=105 | 33 | 87·6 [78·5–96·7] | 89·6 [80·3–98·9] | 97·8 | 0 | NA | NA | 94·6 |
| CCyR N=97 | 33 | 89·8 [81·0–98·6] | 91·9 [82·9–100·9] | 97·7 | 0 | NA | NA | 94·3 |
| MMR N=86 | 28 | 90·9 [82·0–99·9] | 93·0 [83·9–102·2] | 97·7 | 0 | NA | NA | 94·4 |
| MR4·5 N=43 | 15 | 85·6 [70·2–100] | 87·7 [71·9–102·5] | 97·6 | 0 | NA | NA | 94·1 |
| CMR N=23 | 11 | 94·1 [82.9–100] | 96·4 [84·9–102·5] | 97·6 | 0 | NA | NA | 94·2 |
Abbreviations: OS, overall survival; GP, general population; CI, confidence interval; CCyR, complete cytogenetic response; MMR, major molecular response; MR4·5, molecular response with 4·5 log reduction by international scale; CMR, complete molecular response; NA, not applicable.